Category - Developments

Developments

Zenabis receives cultivation license for Langley plant upping capacity by 30%

Zenabis Global (TSX:ZENA) received a cultivation license from Health Canada for its Zenabis Langley plant, adding 9,900 kg of licensed annual cultivation capacity of cannabis at Site A – Part 1 at the facility. The...

August 6, 2019

Developments

AC Immune initiates Phase 1b/2a trial of Alzheimer’s disease vaccine

AC Immune (NASDAQ:ACIU) initiated a Phase 1b/2a clinical trial to evaluate its anti-phospho-Tau vaccine in patients with early Alzheimer’s disease (AD). Targeting pathological Tau, the vaccine is intended as a disease...

August 1, 2019

Developments

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

August 1, 2019

Developments

BTIG cuts Conformis to neutral

BTIG downgraded Conformis (NASDAQ:CFMS) to “neutral” from “buy” following release of the company’s second quarter results. BTIG does not publish price targets on neutral-rated stocks. Conformis, which closed at $2.76 on...

August 1, 2019

Developments

Orchard Therapeutics gets FDA RMAT designation for Wiskott-Aldrich Syndrome drug

Orchard Therapeutics’ (NASDAQ:ORTX) OTL-103 received FDA regenerative medicine advanced therapy (RMAT) designation for the treatment of Wiskott-Aldrich Syndrome (WAS). WAS is an inherited immune disorder where...

July 31, 2019

Developments

Therapix’s CannAmide approved by Health Canada

Therapix Biosciences (NASDAQ:TRPX) reported that Health Canada issued a product license for CannAmide as an anti-inflammatory, and for relief of chronic pain. CannAmide is an immediate release formulation of the...

July 31, 2019

Developments

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

BELLUS Health (TSX:BLU) enrolled the first patient in its Phase 2 study of BLU-5937 for the treatment of chronic cough. The study, called RELIEF, will assess the efficacy, safety, and tolerability of BLU-5937 at four...

July 31, 2019

Developments

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported that the FDA cleared its IND for a Phase 2 trial of ELX-02 in patients with cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF...

July 31, 2019

Developments

Translate Bio reports interim Phase 1/2 cystic fibrosis trial data

Translate Bio (NASDAQ:TBIO) reported interim results from its Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). MRT5005 is inhaled to deliver the gene that encodes functional CF transmembrane...

July 31, 2019

Developments

MediBeacon inks $30-million agreement with Huadong Medicine in greater China

Closely-held MediBeacon and Huadong Medicine (SZ:000963) signed an agreement that will provide Huadong with exclusive rights to MediBeacon’s portfolio of assets in greater China. MediBeacon’s lead program is a point-of...

July 31, 2019

Category - Developments

Zenabis receives cultivation license for Langley plant upping capacity by 30%

AC Immune initiates Phase 1b/2a trial of Alzheimer’s disease vaccine

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

BTIG cuts Conformis to neutral

Orchard Therapeutics gets FDA RMAT designation for Wiskott-Aldrich Syndrome drug

Therapix’s CannAmide approved by Health Canada

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Translate Bio reports interim Phase 1/2 cystic fibrosis trial data

MediBeacon inks $30-million agreement with Huadong Medicine in greater China

General

More